Anticholinergic agent and sympathomimetic amine combination

This page covers all Anticholinergic agent and sympathomimetic amine combination drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Muscarinic acetylcholine receptors (atropine); alpha-1, alpha-2, beta-1, and beta-2 adrenergic receptors (epinephrine).

Targets

Muscarinic acetylcholine receptors (atropine); alpha-1, alpha-2, beta-1, and beta-2 adrenergic receptors (epinephrine)

Marketed (1)

• Atropine sulfate and epinephrine · Dar El Oyoun Hospital · Emergency Medicine / Toxicology
  Atropine blocks muscarinic acetylcholine receptors to reduce parasympathetic effects, while epinephrine stimulates adrenergic receptors to increase heart rate and blood pressure.

Patent intelligence

• anticholinergic agent and sympathomimetic amine combination patent landscape — aggregated cliff calendar, attackable patents, originator estates